Temoporfin

CHEMBL500576 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
680.7 g/mol
LogP
8.8
Phase
4

Temoporfin (mTHPC, Foscan) is a second-generation photosensitizer used in photodynamic therapy (PDT) for head and neck squamous cell carcinoma and non-small cell lung cancer, where it accumulates preferentially in tumor tissue and, upon activation by 652 nm laser light, generates cytotoxic singlet oxygen and free radicals that destroy tumor cells. It is significantly more potent than first-generation porphyrin photosensitizers, requiring lower doses of drug and light. Its primary limitation is prolonged photosensitivity requiring extended sun avoidance after administration.

Berat Molekul

680,7000 g/mol

LogP

8,80

TPSA

138,00 Ų

Lipinski RO5

Gagal

Area Terapeutik

Mekanisme Kerja

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc(c(-c5cccc(O)c5)c5ccc2[nH]5)CC4)C=C3)c1

InChI

InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-

Molecular Formula

C44H32N4O4

HBD / HBA

6 / 6

Ikatan yang Dapat Dirotasi

4

Atom Berat

52

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Temoporfin (mTHPC, Foscan) is a second-generation photosensitizer used in photodynamic therapy (PDT) for head and neck squamous cell carcinoma and non-small cell lung cancer, where it accumulates preferentially in tumor tissue and, upon activation by 652 nm laser light, generates cytotoxic singlet oxygen and free radicals that destroy tumor cells. It is significantly more potent than first-generation porphyrin photosensitizers, requiring lower doses of drug and light. Its primary limitation is prolonged photosensitivity requiring extended sun avoidance after administration.

Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.

Yes, Temoporfin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL500576. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60751. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.